| Methods |
Double‐blind, randomised controlled trial |
| Participants |
General, gynaecologic, neurologic and cardiothoracic.
patients. Both carriers and non‐carriers. Mupirocin: 430 carriers. Placebo: 439 carriers. Patients that received placebo were more likely to have had renal disease (p=0.04). |
| Interventions |
Mupirocin or placebo. Twice daily for up to 5 days, before the operation. |
| Outcomes |
S. aureus infection rate. Mortality. Adverse events. Infection rate caused by other micro‐organisms than S. aureus. |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
Adequate |
| Blinding?
participants |
Low risk |
|
| Blinding?
investigator |
Low risk |
|
| Blinding?
outcome assessor |
Low risk |
|
| Blinding?
data analysis |
Low risk |
|
| Intention to treat |
Low risk |
reported and confirmed |
| Loss to follow up |
Low risk |
Mupirocin 10.4 Placebo 13.2 |
